|Mr. Joshua T. Brumm||CEO, Pres & Director||789.44k||N/A||1978|
|Dr. Romesh Subramanian Ph.D.||Co-Founder & Advisor||565.17k||N/A||1966|
|Ms. Susanna Gatti High M.B.A.||Chief Operating Officer||409.31k||N/A||1968|
|Mr. Gene Kim||VP of Fin.||N/A||N/A||1977|
|Mr. Richard Scalzo||VP of Accounting & Admin. and Treasurer||N/A||N/A||1986|
|Dr. Oxana Beskrovnaya Ph.D.||Chief Scientific Officer||N/A||N/A||1961|
|Ms. Amy Reilly||VP of Corp. Communications & Investor Relations||N/A||N/A||1974|
|Dr. Thomas-Christian Mix M.D., M.S.||Sr. VP of Clinical Devel.||N/A||N/A||1967|
|Ms. Debra Feldman||VP & Head of Regulatory Affairs||N/A||N/A||1971|
|Mr. Daniel Wilson||VP & Head of Intellectual Property||N/A||N/A||1972|
Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. The company was founded in 2017 and is headquartered in Waltham, Massachusetts.
Dyne Therapeutics, Inc.’s ISS Governance QualityScore as of September 26, 2021 is 8. The pillar scores are Audit: 3; Board: 7; Shareholder Rights: 8; Compensation: 9.